Collectively, although the development of adequate systems able to facilitate their delivery remains one of the limiting problems, to date, AMPs potentially possess all the essential features to become the only class of drugs able to fight MDR both in bacterial infections and in cancer. This evidence concerns the gene ADSL and cancer.